JG
LCTX icon

Jefferies Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Jefferies Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,400
Closed -$57.3K – 1838
2021
Q1 		$57.3K Buy
+24,400
New +$58.6K ﹤0.01% 1494
2019
Q3 		– Sell
-10,577
Closed -$12K – 2873
2019
Q2 		$12K Sell
10,577
-76,612
-88% -$88.3K ﹤0.01% 2440
2019
Q1 		$114K Sell
87,189
-132,143
-60% -$164K ﹤0.01% 2085
2018
Q4 		$200K Buy
219,332
+84,948
+63% +$130K ﹤0.01% 1826
2018
Q3 		$276K Buy
134,384
+98,354
+273% +$207K ﹤0.01% 1915
2018
Q2 		$65K Buy
+36,030
New +$72.5K ﹤0.01% 2186

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's LCTX Position: Q2 2021 in Review

Jefferies Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2021, closing a stake of 24,400 shares — an estimated $57.3K sold.

Jefferies Group first reported a position in LCTX in Q2 2018 and held it in 6 quarters. The position peaked at $276K in Q3 2018. 115 funds tracked by Wall St. Rank hold LCTX as of Q2 2021.

  • Jefferies Group reported no remaining Lineage Cell Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 24,400 Lineage Cell Therapeutics shares in Q2 2021, an estimated $57.3K.
  • Jefferies Group first reported a position in Lineage Cell Therapeutics in Q2 2018 and held it in 6 quarters.
  • Jefferies Group's Lineage Cell Therapeutics position peaked at $276K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.